Fig. 8

Assessment of immunotherapy and chemotherapy response related to the anoikis-related signature among OV patients. A The boxplots of the gene expression distribution for 8 typical immune checkpoints, including CTLA4, CD274, LAG3, HAVCR2, SIGLEC15, PDCD1, PDCD1LG2, and TIGIT, between the two risk groups classified by the anoikis-related signature. B The prediction of patient response to immune checkpoint blockade (ICB) therapies, according to the Tumor Immune Dysfunction and Exclusion (TIDE) score. C Based on the PRJEB23709 dataset [20], we compared the distribution of Riskscores among responders and non-responders to anti-CTLA-4 + anti-PD-1 (top) and anti-PD-1 (bottom) immunotherapies. (D) The Kaplan–Meier (K-M) curves for patients classified by the anoikis-related signature, in anti-CTLA-4 + anti-PD-1 (left) and anti-PD-1 (right) cohorts. (E) The violin diagrams of estimated half maximal inhibitory concentration (IC50) values among OV patients, in terms of 8 typical chemotherapies (including Bleomycin, Docetaxel, Cisplatin, Paclitaxel, Gemcitabine, Sorafenib, Veliparib, and Vinblastine). The chemotherapy sensitivity was estimated according to the Genomics of Drug Sensitivity in Cancer (GDSC) database. *P-value < 0.05